专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06613320B1 Defective CD4+T-cells that express active CD40-L 失效
标题翻译：表达活性CD40-L的CD4 + T细胞不良
公开(公告)号：US06613320B1
公开(公告)日：2003-09-02
申请号：US09545993
申请日：2000-04-10
申请人： Melanie K. Spriggs , Richard J. Armitage , William C. Fanslow, III , Michael B. Widmer , Barry L. Davison , Blair R. Renshaw
发明人： Melanie K. Spriggs , Richard J. Armitage , William C. Fanslow, III , Michael B. Widmer , Barry L. Davison , Blair R. Renshaw
IPC分类号： C12N510
CPC分类号： A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0306 , A01K2267/0381 , A61K38/00 , A61K48/00 , C07K14/70575 , C07K19/00 , C07K2319/00 , C07K2319/30 , C12N15/8509 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , Y10S514/885
摘要： CD4+ cells obtained from individuals with defective CD40L gene and transfected with a vector containing CD40-L are described.
摘要翻译：描述了从含有CD40L基因的个体获得并用含有CD40-L的载体转染的CD4 +细胞。

2. 发明授权

US6106832A Treatment of individuals exhibiting defective CD40L 失效
标题翻译：治疗出现CD40L缺陷的个体
公开(公告)号：US6106832A
公开(公告)日：2000-08-22
申请号：US589771
申请日：1996-01-22
申请人： Melanie K. Spriggs , Richard J. Armitage , William C. Fanslow, III , Michael B. Widmer
发明人： Melanie K. Spriggs , Richard J. Armitage , William C. Fanslow, III , Michael B. Widmer
IPC分类号： A61K35/12 , A61K38/00 , A61K39/395 , A61K48/00 , C07K14/705 , C07K19/00 , C12N5/10 , C12N15/85 , C12Q1/68 , A61K38/19
CPC分类号： A01K67/0276 , C07K14/70575 , C07K19/00 , C12N15/8509 , C12Q1/6883 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0306 , A01K2267/0381 , A61K38/00 , A61K48/00 , C07K2319/00 , C07K2319/30 , C12Q2600/156 , C12Q2600/158 , Y10S514/885
摘要： There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating individuals exhibiting a defective CD40 ligand gene (i.e., X-linked hyper IgM patients and certain individuals afflicted with combined variable immunodeficiency) are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
摘要翻译：公开了一种检测CD40配体基因突变的方法，包括分离来自个体的核酸，选择性扩增衍生自CD40配体基因的核酸，并分析扩增的核酸以确定是否存在突变（或突变）在CD40配体基因中。可以测定从该基因表达的CD40配体蛋白的能力。还公开了治疗表现出有缺陷的CD40配体基因（即，X连锁的超IgM患者和某些患有组合的可变免疫缺陷的个体）的个体的方法。还公开了作为基因靶向技术的结果，缺乏功能性CD40配体的非人动物。

3. 发明授权

US5565321A Detection of mutations in a CD40 ligand gene 失效
标题翻译：检测CD40配体基因中的突变
公开(公告)号：US5565321A
公开(公告)日：1996-10-15
申请号：US184422
申请日：1994-01-21
申请人： Melanie K. Spriggs , Richard J. Armitage , William C. Fanslow, III
发明人： Melanie K. Spriggs , Richard J. Armitage , William C. Fanslow, III
IPC分类号： A01K67/027 , A61K31/70 , A61K31/7088 , A61K35/12 , A61K38/00 , A61K48/00 , C07H21/04 , C07K14/705 , C07K19/00 , C12N5/10 , C12N15/09 , C12N15/85 , C12Q1/68 , G01N33/50 , G01N33/566 , C12F19/34
CPC分类号： C12N15/8509 , A01K67/0276 , C07K14/70575 , C07K19/00 , C12Q1/6883 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0306 , A01K2267/0381 , A61K38/00 , A61K48/00 , C07K2319/00 , C12Q2600/156 , C12Q2600/158
摘要： There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating a syndrome that results in elevated levels of serum IgM and diminished levels of all other isotypes of immunoglobulins are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
摘要翻译：公开了一种检测CD40配体基因突变的方法，包括分离来自个体的核酸，选择性扩增衍生自CD40配体基因的核酸，并分析扩增的核酸以确定是否存在突变（或突变）在CD40配体基因中。可以测定从该基因表达的CD40配体蛋白的能力。还公开了治疗导致血清IgM水平升高和免疫球蛋白的所有其他同种型降低的综合征的方法。还公开了作为基因靶向技术的结果，缺乏功能性CD40配体的非人动物。

4. 发明授权

US07405270B2 CD40-Ligand lacking native-pattern glycosylation 失效
标题翻译： CD40-配体缺乏天然模式糖基化
公开(公告)号：US07405270B2
公开(公告)日：2008-07-29
申请号：US10200242
申请日：2002-07-19
申请人： Richard J. Armitage , William C. Fanslow, III , Melanie K. Spriggs
发明人： Richard J. Armitage , William C. Fanslow, III , Melanie K. Spriggs
IPC分类号： C07K14/435
CPC分类号： C12N15/62 , A61K38/00 , C07K14/70575 , C07K16/2875 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/32 , C07K2319/73 , C07K2319/74 , C07K2319/75
摘要： There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.
摘要翻译：公开了可用于提供CD40-L多肽的多肽（CD40-L）和DNA序列，载体和转化的宿主细胞。更具体地，本发明提供了分离的人和鼠CD40-L多肽，其结合CD40受体的胞外结合区并且缺乏天然模式糖基化。

5. 发明授权

US5801227A Antibodies to CD40 失效
标题翻译： CD40抗体
公开(公告)号：US5801227A
公开(公告)日：1998-09-01
申请号：US526014
申请日：1995-09-08
申请人： William C. Fanslow, III , JoDee Zappone , Mark Alderson , Richard J. Armitage
发明人： William C. Fanslow, III , JoDee Zappone , Mark Alderson , Richard J. Armitage
IPC分类号： C12N15/02 , A61K38/00 , A61K39/395 , A61P29/00 , A61P37/06 , C07K16/28 , C12N5/10 , C12P21/08 , C12R1/91 , C07K16/18 , C12N5/12
CPC分类号： C07K16/2878 , A61K38/00 , C07K2317/34 , C07K2319/00
摘要： The present invention provides monoclonal antibodies and binding proteins which specifically bind to CD40 and are capable of blocking binding of CD40 to CD40 ligand.
摘要翻译：本发明提供单克隆抗体和结合蛋白，其特异性结合CD40并能够阻断CD40与CD40配体的结合。

6. 发明授权

US5674492A Method of preventing or treating disease characterized by neoplastic cells expressing CD40 失效
标题翻译：预防或治疗以表达CD40的肿瘤细胞为特征的疾病的方法
公开(公告)号：US5674492A
公开(公告)日：1997-10-07
申请号：US360923
申请日：1994-12-21
申请人： Richard J. Armitage , William C. Fanslow, III , Dan L. Longo , William J. Murphy
发明人： Richard J. Armitage , William C. Fanslow, III , Dan L. Longo , William J. Murphy
IPC分类号： C12N15/02 , A61K38/00 , A61K39/395 , A61P35/00 , C07K14/47 , C07K14/705 , C07K16/28 , C07K16/30 , C07K16/46 , C07K19/00 , C12P21/08 , A61K35/12 , A61K38/02
CPC分类号： C07K16/28 , C07K14/705 , C07K14/70575 , C07K16/2878 , A61K38/00 , C07K2317/73
摘要： There is disclosed a method of treating a mammal afflicted with a disease characterized by neoplastic cells that express CD40, comprising administering a therapeutically effective amount of a CD40 binding protein in a pharmaceutically acceptable buffer. CD40 binding proteins include monoclonal antibodies to CD40, and CD40 ligand. CD40 binding proteins may also be used to prevent disease characterized by neoplastic cells that express CD40, in individuals at risk for such disease.
摘要翻译：公开了一种治疗以特征在于表达CD40的肿瘤细胞的疾病的哺乳动物的方法，其包括在药学上可接受的缓冲液中施用治疗有效量的CD40结合蛋白。 CD40结合蛋白包括CD40单克隆抗体和CD40配体。 CD40结合蛋白也可用于预防在具有这种疾病风险的个体中表达CD40的肿瘤细胞特征的疾病。

7. 发明申请

US20110020267A1 TWEAK RECEPTOR 失效
公开(公告)号：US20110020267A1
公开(公告)日：2011-01-27
申请号：US12899397
申请日：2010-10-06
申请人： Kristine M. Kim , Steven R. Wiley , Randal R. Ketchem , William C. Fanslow, III
发明人： Kristine M. Kim , Steven R. Wiley , Randal R. Ketchem , William C. Fanslow, III
IPC分类号： A61K39/395 , A61P35/00 , A61P35/02 , A61K38/19 , A61K38/20 , A61K38/21
CPC分类号： A61K39/3955 , A61K38/00 , C07K14/705 , C07K14/70575 , C07K14/70578 , C07K16/2878 , C07K2319/00 , C07K2319/30 , C07K2319/73
摘要： The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
摘要翻译：本发明提供TWEAK受体和用于鉴定和使用TWEAK受体的激动剂和拮抗剂的方法。特别地，本发明提供筛选激动剂和拮抗剂并用于治疗血管生成介导的疾病或病症的方法，例如实心瘤和心脏或外周组织的血管缺陷。

8. 发明授权

US07193058B2 ULBP antibodies 失效
标题翻译： ULBP抗体
公开(公告)号：US07193058B2
公开(公告)日：2007-03-20
申请号：US10875869
申请日：2004-06-23
申请人： David J. Cosman , Jurgen Mullberg , William C. Fanslow, III , Marek Kubin , Richard Jeffrey Armitage
发明人： David J. Cosman , Jurgen Mullberg , William C. Fanslow, III , Marek Kubin , Richard Jeffrey Armitage
IPC分类号： C07K16/00 , C07K16/18 , C12N5/12 , C12P21/08
CPC分类号： C07K16/28 , A61K38/00 , C07K14/705 , C07K2319/00 , C07K2319/30
摘要： The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-γ production, NK cell proliferation, and CTL activity.
摘要翻译：本发明涉及纯化和分离的新型ULBP多肽，编码此类多肽的核酸，生产此类多肽的重组形式的方法，针对这些多肽产生的抗体，衍生自这些多肽的片段化肽以及上述用途。 ULBP多肽可以在人B细胞淋巴瘤的表面上发现。提供分离或纯化形式的ULBP多肽的哺乳动物形式。此外，提供了编码ULBP多肽的分离的核酸和包含编码ULBP多肽的cDNA的表达载体。 ULBP多肽可以被分离或合成并用于制备针对多肽的抗体，特别是单克隆抗体。抗体又可用于检测人细胞样品中ULBP多肽的存在，这可与患者中恶性病症的存在相关。 ULBP多肽刺激IFN-γ产生，NK细胞增殖和CTL活性。

9. 发明授权

US07074408B2 Use of integrin antagonists to inhibit angiogenesis 失效
标题翻译：使用整联蛋白拮抗剂抑制血管发生
公开(公告)号：US07074408B2
公开(公告)日：2006-07-11
申请号：US09792200
申请日：2001-02-23
申请人： William C. Fanslow, III , Douglas P. Cerretti , Kurt M. Poindexter , Roy A. Black
发明人： William C. Fanslow, III , Douglas P. Cerretti , Kurt M. Poindexter , Roy A. Black
IPC分类号： A61K35/00 , A61K38/00
CPC分类号： C12N9/6489 , A61K38/00 , C07K14/705
摘要： The present invention provides methods and compositions for inhibiting the biological activity of integrins, for inhibiting endothelial cell migration. and for inhibiting angiogenesis. In particular, the invention provides compositions comprising ADAM disintegrin domains and methods for using said compositions. In preferred embodiments the methods and compositions of the invention are used to inhibit angiogenesis and to treat diseases or conditions mediated by angiogenesis.
摘要翻译：本发明提供用于抑制整联蛋白的生物学活性的方法和组合物，用于抑制内皮细胞迁移。并用于抑制血管发生。特别地，本发明提供包含ADAM去整合素结构域的组合物和使用所述组合物的方法。在优选的实施方案中，本发明的方法和组合物用于抑制血管发生和治疗由血管发生介导的疾病或病症。

10. 发明授权

US06774224B2 ULBP DNA and polypeptides 失效
标题翻译： ULBP DNA和多肽
公开(公告)号：US06774224B2
公开(公告)日：2004-08-10
申请号：US10212507
申请日：2002-08-05
申请人： David J. Cosman , Jurgen Mullberg , William C. Fanslow, III , Marek Kubin , Richard Jeffrey Armitage
发明人： David J. Cosman , Jurgen Mullberg , William C. Fanslow, III , Marek Kubin , Richard Jeffrey Armitage
IPC分类号： C07H2100
CPC分类号： C07K16/28 , A61K38/00 , C07K14/705 , C07K2319/00 , C07K2319/30
摘要： The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient. ULBP polypeptides stimulate IFN-&ggr; production, NK cell proliferation, and CTL activity.
摘要翻译：本发明涉及纯化和分离的新型ULBP多肽，编码此类多肽的核酸，生产此类多肽的重组形式的方法，针对这些多肽产生的抗体，衍生自这些多肽的片段化肽以及上述用途。 ULBP多肽可以在人B细胞淋巴瘤的表面上发现。提供分离或纯化形式的ULBP多肽的哺乳动物形式。此外，提供了编码ULBP多肽的分离的核酸和包含编码ULBP多肽的cDNA的表达载体。 ULBP多肽可以被分离或合成并用于制备针对多肽的抗体，特别是单克隆抗体。抗体又可用于检测人细胞样品中ULBP多肽的存在，这可与患者中恶性病症的存在相关。 ULBP多肽刺激IFN-γ产生，NK细胞增殖和CTL活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式